Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2020; 41(04): 555-558
DOI: 10.4103/ijmpo.ijmpo_260_20
Drug Review

Venetoclax – The Game-changer in Hematology

Contributor(s):
Tanmoy Kumar Mandal
Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha Cancer Hospital, Varanasi, Uttar Pradesh, India
,
Somnath Roy
Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha Cancer Hospital, Varanasi, Uttar Pradesh, India
,
Lingaraj Nayak
Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha Cancer Hospital, Varanasi, Uttar Pradesh, India
,
B K Mishra
Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha Cancer Hospital, Varanasi, Uttar Pradesh, India
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
   Permissions and Reprints

Abstract

The introduction of small molecule inhibitors in many hematological malignancies made a landmark achievement in this field with a dramatic change in the survival outcome. Venetoclax is a B-cell lymphoma-2 inhibitor which has become the game-changer molecule in chronic lymphocytic leukemia and acute myeloid leukemia. This review is intended to summarize the mechanism of action, side effects, dosage, and different phases of clinical trials of this drug with review of literature.

Keywords

Acute myeloid leukemia - B-cell lymphoma-2 inhibitor - chronic lymphocytic leukemia - venetoclax


Publication History

Received: 26 May 2020

Accepted: 11 August 2020

Article published online:
17 May 2021

© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M. et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019; 144: 1941-53
    CrossrefPubMedGoogle Scholar
  • 2 Martens U. Small Molecules in Hematology. USA: Springer Nature; 2018
    CrossrefGoogle Scholar
  • 3 Brody T. FDA's Drug Review Process and the Package Label: Strategies for Writing Successful FDA Submissions. United Kingdom: Academic Press, Elsevier Science Publishing Co.; 2017
    Google Scholar
  • 4 Scheffold A, Jebaraj BMC, Stilgenbauer S. Venetoclax: Targeting BCL2 in Hematological Cancers. Recent Results Cancer Res 2018; 212: 215-42
    CrossrefPubMedGoogle Scholar
  • 5 Lenz G, Salles G. Aggressive Lymphomas. USA: Springer International Publishing; 2018
    Google Scholar
  • 6 Fairbrother WJ, Leverson JD, Sampath D, Souers AJ. Discovery and Development of Venetoclax, a Selective Antagonist of BCL-2. Successful Drug Discovery. edited by János Fischer. et al 1st ed. Wiley; 2019: 225-45 DOI.org (Crossref),
    Google Scholar
  • 7 Anderson MA, Deng J, Seymour JF, Tam C, Kim SY, Fein J. et al. The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood 2016; 127: 3215-24
    CrossrefPubMedGoogle Scholar
  • 8 Ackler S, Oleksijew A, Chen J, Chyla BJ, Clarin J, Foster K. et al. Clearance of systemic hematologic tumors by venetoclax (Abt-199) and navitoclax. Pharmacol Res Perspect 2015; 3: e00178
    CrossrefPubMedGoogle Scholar
  • 9 Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF. et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N Engl J Med 2016; 374: 311-22
    CrossrefPubMedGoogle Scholar
  • 10 Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G. et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med 2019; 380: 2095-103
    CrossrefPubMedGoogle Scholar
  • 11 Seymour JF, Kipps TJ, Eichhorst B, Hillmen P, D'Rozario J, Assouline S. et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 2018; 378: 1107-20
    CrossrefPubMedGoogle Scholar
  • 12 A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Subjects With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy - Full Text View - ClinicalTrials. Gov.. https://clinicaltrials.gov/ct2/show/NCT02993523 Available from: [Last accessed 2020 Aug 20]
    Google Scholar
  • 13 Davids MS, Chatterjee A, Ravelo A, Shapouri S, Manzoor BS, Sail K. et al. Cost-effectiveness of a 12-month fixed duration of venetoclax in combination with obinutuzumab in first-line chronic lymphocytic Leukemia in the United States. Blood 2019; 134 Suppl 1: 4741
    CrossrefGoogle Scholar
  • 14 Eyre TA, Walter HS, Iyengar S, Follows G, Cross M, Fox CP. et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy. Haematologica 2019; 104: e68-e71
    CrossrefPubMedGoogle Scholar
  • 15 Morschhauser F, Feugier P, Flinn IW, Gasiorowski RE, Greil R, Illés Á. Venetoclax plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) improves outcomes in BCL2-positive first-line diffuse large B-cell lymphoma (DLBCL):First safety, efficacy and biomarker analyses from the phase II CAVALLI study. Blood. 2018; 132: 782 et al. (supplement 1)
    CrossrefPubMedGoogle Scholar
  • 16 Zinzani PL, Flinn IW, Yuen S, Topp MS, Rusconi C, Fleury I. Efficacy and safety of venetoclax (Ven) + rituximab ® or Ven + Bendamustine (B) + R randomized versus B + R in Patients (pts) with relapsed/refractory (R/R) follicular lymphoma (FL): Final analysis of phase II CONTRALTO study. Blood 2018; 132: 1614 et al. Suppl 1
    CrossrefPubMedGoogle Scholar
  • 17 Wong KY, Chim CS. Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma. J Pharm Pharmacol 2020; 72: 728-37
    CrossrefPubMedGoogle Scholar